Gladstone Investigator Awarded Two Early-Career Grants
Gladstone Investigator Awarded Two Early-Career Grants
Funds will support Isha Jain’s innovative disease research with potential for big impact
Grants Cardiovascular Disease Jain Lab31 - 45 of 89 Results Clear All
Funds will support Isha Jain’s innovative disease research with potential for big impact
Grants Cardiovascular Disease Jain LabGladstone researchers discover how to reverse cardiac scarring—and how this could treat heart failure
News Release Research (Publication) Heart Failure Cardiovascular Disease Alexanian Lab Srivastava Lab CRISPR/Gene EditingA new human organoid developed by Gladstone scientists mimics one of the key steps in early embryonic development
News Release Research (Publication) Cardiovascular Disease McDevitt Lab CRISPR/Gene Editing Stem Cells/iPSCsGladstone researchers design a new artificial intelligence approach to simultaneously follow hundreds of cells in the lab as they divide, move, and interact
News Release Research (Publication) Cardiovascular Disease McDevitt Lab AIWatch presentations from the Bruneau Lab 20th Anniversary Symposium held on March 19, 2021, via Zoom
Cardiovascular Disease Bruneau LabGladstone scientists discover how the novel coronavirus damages heart muscle cells, and create a system that can be used to screen potential therapies
News Release Research (Publication) COVID-19 Cardiovascular Disease Virology Conklin Lab McDevitt Lab Ott LabABC7 News—Gladstone President Deepak Srivastava, MD, a pediatric cardiologist, explains how his group discovered a potential new drug to treat a debilitating disease due to the hardening of heart valves.
Gladstone Experts Congenital Heart Disease Cardiovascular Disease Srivastava Lab Stem Cells/iPSCsA scientist since childhood, Jain will now lead a lab at Gladstone to study the balance of oxygen levels in the human body
Institutional News News Release Profile Cardiovascular Disease Jain LabThe findings could point toward new ways to prevent or treat one of the most common birth defects
News Release Research (Publication) Congenital Heart Disease Cardiovascular Disease Bruneau Lab Human Genetics Stem Cells/iPSCsA drug candidate found by Gladstone researchers could help prevent tens of thousands of heart surgeries every year
News Release Research (Publication) Heart Failure Cardiovascular Disease Srivastava Lab Theodoris Lab AI CRISPR/Gene Editing Disease Models Stem Cells/iPSCsUSA Today—California Proposition 14 put funding for the Stem Cell Research Institute on the ballot this year. Gladstone President Deepak Srivastava, MD, explains how previous funding for stem cell research in California has helped bring the field to a point where stem cell–based therapies are now possible.
Gladstone Experts Cardiovascular Disease Srivastava Lab Stem Cells/iPSCsBenoit Bruneau and Katie Pollard study DNA folding to identify the genetic causes of congenital heart disease
Grants News Release Congenital Heart Disease Cardiovascular Disease Data Science and Biotechnology Bruneau Lab Pollard Lababc News—Gladstone President Deepak Srivastava, MD, comments on the fact that the experimental treatments President Trump received for COVID-19 were tested on cells that were derived from fetal tissue decades ago, and expresses concern that the Trump administration's current ban on the use of fetal tissue for research could slow efforts to curb the pandemic.
Gladstone Experts COVID-19 Cardiovascular Disease Srivastava LabThe New York Times—The experimental drugs used to treat President Trump for COVID-19 were developed with the help of a human cell line derived from a fetus aborted decades ago. Gladstone President Deepak Srivastava, MD, and Senior Investigator Warner Greene, MD, PhD, comment on the ethics of accepting this treatment while also banning research using newly derived fetal cells, in the process thwarting the development of life-saving treatments for other conditions.
Gladstone Experts COVID-19 Cardiovascular Disease Center for HIV Cure Research Greene Lab Srivastava LabSan Francisco Business Times—As Scribe Therapeutics Inc., the latest company founded by Senior Investigator Jennifer Doudna, PhD, announced that it landed a deal with Biogen Inc., Gladstone President Deepak Srivastava, MD, commented on the importance of CRISPR-based biotech companies for medicine and agriculture and on Doudna’s drive as a scientist.
Gladstone Experts Cardiovascular Disease Data Science and Biotechnology Doudna Lab Srivastava Lab CRISPR/Gene Editing